Prostatic Neoplasm
73
8
11
45
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
16 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.0%
8 terminated out of 73 trials
84.9%
-1.6% vs benchmark
4%
3 trials in Phase 3/4
36%
16 of 45 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 45 completed trials
Clinical Trials (73)
PSMA PET Combined With MRI for the Detection of PCa
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies
Investigation of Impact of AI on Prostate Cancer Workflow
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
EBRT + Lu-PSMA for N1M0 Prostate Cancer
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Impact of Augmented Reality During Robot-assisted Radical Prostatectomy
Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Prostate Cancer Genetic Risk Evaluation and Screening Study